Conditions: Healthy
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 60
Healthy volunteers: yes

Brief summary:
The objective of the current study is to investigate if a drug-drug interaction occurs with the administration of omeprazole 80 mg q.d. at steady state on the pharmacokinetics of dipyridamole and the pharmacodynamics of ASA-induced platelet aggregation inhibition (components of Aggrenox®) when administered every 12 hours at steady state.

Detailed description:
Purpose:

Arms:
arm 1: Aggrenox alone arm 2: Aggrenox and omeprazole arm 3: Omeprazole alone arm 4: Aggrenox and omeprazole

Interventions: intervention 1: Aggrenox alone intervention 2: Aggrenox and omeprazole intervention 3: Aggrenox and omeprazole intervention 4: Omeprazole alone
Intervention descriptions: intervention 1: Aggrenox 1 capsule twice daily for 7 days intervention 2: Aggrenox 1 capsule twice daily and omeprazole 80mg once daily for 7 days intervention 3: Aggrenox 1 capsule twice daily and omeprazole 80mg once daily for 7 days intervention 4: omeprazole 80 once daily for 7 days

Protocol document: